Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)

NCT01171898 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

127

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: ARN-509 (Phase 1)
DRUG: ARN-509 (Phase 2)

Sponsor

Aragon Pharmaceuticals, Inc.